JCO oncology practice最新文献

{"title":"No Versus Know: Patient Empowerment Through Shared Decision Making.","authors":"Beatrice T B Preti","doi":"10.1200/OP-25-00500","DOIUrl":"https://doi.org/10.1200/OP-25-00500","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500500"},"PeriodicalIF":4.6,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Ambulatory Oncology Clinical Pharmacy Key Performance Indicators Using a Modified Delphi Consensus Approach.","authors":"Thomas McFarlane, Rozhannaa Sothilingam, Olavo Fernandes, Sherilyn K D Houle, Jennifer Lo, Shirin Abadi, Scott Edwards, Michael LeBlanc, Jason Wentzell, Bryanna Tibensky, Carlo DeAngelis, Lauren Steeves","doi":"10.1200/OP-25-00353","DOIUrl":"https://doi.org/10.1200/OP-25-00353","url":null,"abstract":"<p><strong>Purpose: </strong>To develop evidence-based ambulatory oncology clinical pharmacy key performance indicators (AOcpKPIs).</p><p><strong>Methods: </strong>A systematic, modified Delphi process was used to reach consensus on AOcpKPIs. Following an environmental scan of current oncology pharmacy practices across Canada, a literature review identified critical activities linked to patient-centered outcomes. A panel of oncology pharmacists engaged in three Delphi rounds and a virtual live meeting, assessing and refining candidate AOcpKPIs on the basis of predefined criteria. A total of 17 candidate AOcpKPIs were evaluated.</p><p><strong>Results: </strong>Consensus was achieved on 14 AOcpKPIs. These AOcpKPIs reflect critical pharmacist activities including clinical order review, patient education, medication adherence assessment, and management of drug therapy problems. This suite of AOcpKPIs provides a standardized approach for evaluating oncology pharmacist activities in ambulatory care, facilitating benchmarking and supporting evidence-based improvements in patient outcomes.</p><p><strong>Conclusion: </strong>This study represents a significant advancement in defining quality metrics for ambulatory oncology pharmacy practice. The consensus-based AOcpKPIs provide a foundation for enhanced patient care, professional accountability, and continuous quality improvement within oncology pharmacy. Implementing these AOcpKPIs has the potential to elevate oncology pharmacy practice, supporting pharmacists in meeting evolving health care demands and fostering evidence-based patient outcomes.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500353"},"PeriodicalIF":4.6,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teaching Communication Skills and Developing Comfort With Difficult Conversations: A Combined Palliative Care-Oncology Simulation Session for Hematology/Oncology Fellows.","authors":"Megan M Dupuis, Katherine J Walsh, Rajiv Agarwal","doi":"10.1200/OP-25-00104","DOIUrl":"https://doi.org/10.1200/OP-25-00104","url":null,"abstract":"<p><strong>Purpose: </strong>ASCO strongly endorses the integration of palliative care (PC) to improve outcomes and support patients in their cancer trajectories. Developing core PC skills for trainees is essential, with few Accreditation Council of Graduate Medical Education-approved pilot programs offering combined fellowship training. Our institution's hematology/oncology (Heme/Onc) fellows reported a need for additional education in leading difficult conversations.</p><p><strong>Methods: </strong>We designed and piloted a didactic simulation (sim) session for each fellowship class, led by a faculty member who is dual board-certified in Medical Oncology and Hospice/Palliative Medicine. Sessions included an overview of validated communication tools, suggested oncology-specific language, small-group case-based role-play with faculty supervision and feedback, and concluded with class reflection. Pre- and post-sim surveys assessed self-reported awareness of communication tools and comfort in discussing difficult oncology-specific topics.</p><p><strong>Results: </strong>In year 1, 16 (76.2%) of 21 fellows completed pre- and post-sim surveys. In year 2, 15 (71.4%) of 21 and 19 (90.4%) of 21 completed pre- and post-sim surveys, respectively. Fellow awareness of communication tools in year 1 increased from 21.9% pre-sim to 79.7% post-sim (<i>P</i> < .05); whereas in year 2, baseline awareness was much higher at 62.6% but still increased to 76.3% post-sim, with notable increase for prognostic discussion tools (<i>P</i> < .05). Comfort increased across multiple domains of difficult conversations in both years 1 and 2 (<i>P</i> < .05). Overall, trainees reported that the sim sessions were useful. Those who participated in the pilot year confirmed application of communication techniques in their clinical practice.</p><p><strong>Conclusion: </strong>Dedicated and iterative communication teaching in Heme/Onc fellowship is imperative for the development of future generations of oncologists. Our sim session leads to sustained improvement in trainee awareness of communication tools and comfort for leading difficult oncology conversations.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500104"},"PeriodicalIF":4.6,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer.","authors":"Rotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, Mark Carty, Akash Mitra, Halla Nimeiri, Ira Klein, Rafi Pelossof, Daniel Morgensztern","doi":"10.1200/OP-25-00718","DOIUrl":"https://doi.org/10.1200/OP-25-00718","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500718"},"PeriodicalIF":4.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artful Oncology: A Comprehensive Psychosocial Oncology Curriculum for Hematology/Oncology Fellows.","authors":"Jafar Al-Mondhiry, Kimberly Lowery Walker, Jennifer Bires, Leigh Ann Caulkins, Cheryl Hughes, Denise Mohess, Raymond Wadlow","doi":"10.1200/OP-25-00114","DOIUrl":"https://doi.org/10.1200/OP-25-00114","url":null,"abstract":"<p><strong>Purpose: </strong>Forty-six percent of patients with cancer experience significant psychosocial distress, a factor linked to higher morbidity, mortality, and costs of care. Oncologists also face high psychosocial distress, particularly during fellowship training. Herein, we describe a novel curriculum aimed at improving the professional well-being, communication skills (CS), and attitudes toward psychosocial patient care among hematology/oncology (H/O) fellows.</p><p><strong>Methods: </strong>Artful Oncology is an innovative, multimodal, longitudinal curriculum for H/O fellows consisting of four pillars: (1) monthly psychosocial oncology didactics; (2) bimonthly narrative medicine seminars; (3) quarterly CS training simulations; and (4) monthly cancer survivorship support group facilitation. This curriculum was introduced with the inaugural H/O fellowship class in 2021 with formal assessments added in 2022-2023 (total six fellows). Outcomes were measured through self-assessed CS, scored feedback for each didactic, annual Physician Belief Scale (PBS) surveys, quarterly Professional Quality of Life (ProQOL)-Health, and abbreviated Maslach Burnout Inventory (MBI) surveys.</p><p><strong>Results: </strong>Fellows rated didactics as being relevant to their work, prepared to implement the skills learned into clinical practice, and would recommend these sessions to others (average 4.59, 4.48, and 4.67 of 5-point Likert scale, respectively). PBS scores numerically improved from 2022 to 2023 (78 to 68.8 of 160). MBI and ProQOL Health scores were largely unchanged (<2 point difference on average). Self-assessed CS averaged across rising fellows increased from 4.38 to 7.44 of 10 between 2022 and 2023.</p><p><strong>Conclusion: </strong>Self-assessed CS and physician attitudes regarding psychosocial care numerically improved after participation in the Artful Oncology curriculum. Didactic sessions were rated as highly relevant, actionable, and recommended by H/O fellows. Study of this curriculum over a longer timeframe with larger numbers of fellows is ongoing to better evaluate effects.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500114"},"PeriodicalIF":4.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmet Social Needs Among Cancer Survivors Who Were Concomitant Caregivers: A Cross-Sectional Analysis of the Health Information National Trends Survey.","authors":"Qian Wang, Zhiting Tang, Hui Xie, Chi Wen, Yannan Li, Changchuan Jiang, Lauren Chiec, Sara L Douglas, Melinda L Hsu","doi":"10.1200/OP-25-00388","DOIUrl":"https://doi.org/10.1200/OP-25-00388","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to examine the impact of social determinants of health (SDOH) barriers, including food, housing, and transportation insecurities, on cancer survivors who also serve as caregivers (dual roles), compared with cancer survivors only, caregivers only, and the general population. A secondary aim was to assess their comfort level in sharing these barriers with health care providers.</p><p><strong>Methods: </strong>Data were obtained from the 2022 National Cancer Institute Health Information National Trends Survey (HINTS 6), which collected information on SDOH outcomes, including food, housing, and transportation insecurities, as well as participants' comfort level in sharing their SDOH concerns with providers. We compared these outcomes across four groups: dual roles, cancer survivors only, caregivers only, and the general population. Weighted multivariable logistic regression models were used to calculate the adjusted odds ratio (aOR) of SDOH factors by cancer survivor/caregiver status.</p><p><strong>Results: </strong>Overall, 49.1% of dual roles reported facing at least one form of food, housing, or transportation insecurities. Dual roles were 4.61 (aOR, 4.61 [95% CI, 2.71 to 7.84]) and 9.45 (aOR, 9.45 [95% CI, 4.45 to 20.07]) times more likely to report one or more of the above SDOH barriers compared with the general population and cancer survivors only, respectively. However, dual roles did not appear to feel more comfortable in sharing their barriers with health care providers compared with other groups.</p><p><strong>Conclusion: </strong>Our study highlights the significant unmet needs of cancer survivors who also serve as caregivers, as they face higher levels of SDOH barriers than both the general population and cancer survivors only. However, they did not have a greater comfort level in sharing them with providers, underscoring the necessity for targeted strategies to address the unique challenges faced by this vulnerable population.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500388"},"PeriodicalIF":4.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Drug Shortages on Cancer Care Delivery Within the National Cancer Institute Community Oncology Research Program.","authors":"Lauren V Ghazal, Supriya Mohile, Kah Poh Loh, Karen Mustian, Grace Sventek, Umang Gada, Chin-Shang Li, Eva Culakova, Melyssa Foust, Judith O Hopkins, Heather Kehn, Charles Kamen, Erin R Fox, Elaine L Hill","doi":"10.1200/OP-25-00057","DOIUrl":"10.1200/OP-25-00057","url":null,"abstract":"<p><strong>Purpose: </strong>Drug shortages represent a challenge in oncology care, with potential repercussions including suboptimal treatment options, treatment delays, and medication errors. However, there is scant evidence on how drug shortages interrupt cancer care delivery (CCD) nationally and specifically across National Cancer Institute (NCI) Community Oncology Research Program (NCORP) community oncology practices.</p><p><strong>Methods: </strong>Between December 2020 and July 2024, 96 NCORP community oncology practices were enrolled. NCORP practice study staff completed the Drug Shortage Baseline Survey and Pharmacy Baseline Survey. The primary outcome was proportion of practices seriously affected by drug shortages (ie, encountered CCD problems [change to less effective treatments, adoption of more toxic alternatives, treatment delays, or an increase in medication errors or near misses]) in the past 3 months. Secondary outcomes included CCD problems among practices (eg, ethical dilemmas) and strategies used by practices (eg, use of alternative drugs, stockpiling). Finally, we described differences between seriously affected and nonaffected practices.</p><p><strong>Results: </strong>Nearly 54% of NCORP practices were seriously affected by drug shortages in the past 3 months, with 23 drugs (including carboplatin [24.7%], leucovorin [22.6%], and cisplatin [19.4%]). Seriously affected practices were more likely to report lack of suitable alternatives (34.7% <i>v</i> 13.6%), substantial resources spent (70.8% <i>v</i> 50.0%), and change to alternative administration (73.5% <i>v</i> 52.3%) and were less likely to hire staff to address shortages (16.3% <i>v</i> 36.4%). Strategies to address shortages included using alternative drugs (91.5%), stockpiling (87.2%), and developing action plans (84.0%). Most (50.5%) practices reported experiencing an ethical dilemma related to a drug shortage.</p><p><strong>Conclusion: </strong>Drug shortages influenced CCD among NCORP practices. This study underscores the need for robust strategies and policies to mitigate these effects and enhance the resilience of oncology practices.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500057"},"PeriodicalIF":4.6,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Derivation and External Validation of Objective Performance Status Among Patients With Metastatic Cancer.","authors":"Eva Ruiz, Christopher R Manz, Anthony Girard, Tatiana Hernández-Guerrero, Bernard Doger De-Speville, Daniel Morillo, Ignacio Mahíllo-Fernández, Jesus García-Foncillas, Eric Li, William J Ferrell, Ian Barnett, Victor Moreno, Ravi B Parikh","doi":"10.1200/OP-25-00195","DOIUrl":"https://doi.org/10.1200/OP-25-00195","url":null,"abstract":"<p><strong>Purpose: </strong>Performance status (PS) assessment is used to determine clinical trial eligibility among patients with cancer, but may be inaccurately assessed by oncology clinicians. Wearable accelerometers may allow objective assessment of physical activity, a proxy for PS. In this analysis of two prospective studies, we derive and externally validate objective PS (OPS) by measuring the association between daily physical activity and overall survival among patients with metastatic cancer.</p><p><strong>Materials and methods: </strong>For the derivation cohort, we prospectively measured daily physical activity using a wearable accelerometer among patients with metastatic cancer during the screening period for a phase 1 clinical trial in Spain. We used univariable survival analysis, AUCs, and Youden's index to derive an OPS cutoff in mean daily distance walked. We used a multivariable Cox model to calculate the association between OPS and 180-day mortality. We subsequently externally validated OPS in a separate prospective trial of patients with metastatic lung and GI cancers receiving chemotherapy at a large academic health center in the United States.</p><p><strong>Results: </strong>Full data were available for 123 patients (70 derivation; 53 validation). In the derivation cohort, we defined an OPS cutoff at 1,200 m walked per day. Poor OPS was associated with higher mortality than good OPS in the derivation (180-day mortality, 81.6% <i>v</i> 38.4%; adjusted hazard ratio [aHR], 6.82 [95% CI, 3.44 to 13.5]; <i>P</i> < .001) and external validation cohorts (180-day mortality, 36% <i>v</i> 8%; aHR, 7.07 [95% CI, 1.37 to 36.6]; <i>P</i> = .02).</p><p><strong>Conclusion: </strong>OPS is an independent, externally validated prognostic indicator and could serve as an objective surrogate for traditional methods of PS assessment in clinical trials and choice of therapy for patients with cancer.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500195"},"PeriodicalIF":4.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality Improvement Effort With Proactive Social Worker Communication to Enhance Palliative Care Access.","authors":"Ellis C Dillon, Amandeep Grewal, Su-Ying Liang, Harold Luft, Martina Li, Natalia Colocci, Steve Lai, Manali I Patel","doi":"10.1200/OP-25-00077","DOIUrl":"https://doi.org/10.1200/OP-25-00077","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates a quality improvement project to improve access to specialty palliative care (PC) for individuals with advanced cancer.</p><p><strong>Methods: </strong>A California health care organization implemented a social worker (SW)-led program to improve education about, and referrals to, PC for patients with advanced cancer at one clinic (intervention site), whereas three control sites continued usual care. We used a rigorous intention-to-treat difference-in-difference analysis to detect whether the intervention increased PC referrals (primary outcome) at the intervention versus control sites while accounting for preimplementation trends. We used multivariable logistic and Poisson regressions to compare primary and exploratory outcomes (advance care planning and end-of-life outcomes: PC visits before death, acute care use within 30 days of death, and systemic therapy within 14 days of death) in the preimplementation and postimplementation period.</p><p><strong>Results: </strong>The analytic cohort included 555 patients (177 preimplementation, 378 postimplementation): 147 (26.5%) at the intervention site and 408 at control sites, with 312 (56.2%) deceased. At the intervention site postimplementation, 52 (51.5%) of 101 patients received the SW-led intervention. At the intervention site, PC referrals increased from 30.4% to 32.7% (<i>v</i> 26.7% to 25.3% at control sites). PC visits increased from 21.7% to 28.7% (<i>v</i> 21.4% to 22%), and among decedents, any PC visits increased from 53.1% to 75% (<i>v</i> 57% to 66.9%). In adjusted multivariable analyses, the only near-significant difference-in-difference PC effect was that decedents at the intervention site had higher odds of receiving PC before death (OR, 3.09 [95% CI, 0.89 to 10.67]; <i>P</i> = .07).</p><p><strong>Conclusion: </strong>This SW-led intervention was not associated with significantly increased PC referrals. When translating evidence from trials to real-world quality improvement efforts, context and changes to the intervention may affect effectiveness.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500077"},"PeriodicalIF":4.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Preferences on Clinical Decision Making in Multiple Myeloma.","authors":"Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Katherine Berger, Ryan Winborg, Mason S Barnes, Jorge Arturo Hurtado Martinez, Jay R Hydren, Douglas Sborov, Amandeep Godara, Brian McClune, Christopher M Booth, Edward R Scheffer Cliff","doi":"10.1200/OP-25-00322","DOIUrl":"https://doi.org/10.1200/OP-25-00322","url":null,"abstract":"<p><strong>Purpose: </strong>To better understand the priorities that guide patients with multiple myeloma, we surveyed patients on four different treatment scenarios, each of treatment strategies shown to improve progression-free survival (PFS) but offering similar overall survival (OS) outcomes.</p><p><strong>Methods: </strong>We conducted a survey using the HealthTree Cure Hub by the HealthTree Foundation, the largest online portal for people with plasma cell dyscrasias.</p><p><strong>Results: </strong>The primary analysis cohort included 466 participants with myeloma, while an additional 297 responses from patients with smoldering myeloma or monoclonal gammopathy of uncertain significance were analyzed separately. When presented with either three-drug or four-drug frontline treatment for their myeloma, where four drugs offered better PFS, similar OS, and slightly increased toxicity, 56% of participants chose four drugs. For one-off consolidation treatment after induction, analogous to autologous transplant, which improved PFS but not OS, 50% of participants chose the consolidation. For maintenance therapy, where maintenance with two drugs offered better PFS, but similar OS and increased toxicity than one drug, 17% of participants chose two-drug maintenance. When evaluating a scenario for multiply relapsed disease, where a treatment improved PFS with increased toxicity, and no impact on OS, 7% of participants elected to receive this treatment.</p><p><strong>Conclusion: </strong>Our findings show that many patients choose not to receive treatments that improve PFS if they do not positively affect OS and lead to substantial clinical, financial, and/or time toxicities.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500322"},"PeriodicalIF":4.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}